
|Articles|March 12, 2014
- Immunotherapy (Issue 2)
- Volume 2
- Issue 1
How Immunotherapies are Changing the Treatment of Melanoma
Author(s)Harriet Kluger, MD
Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, explains how immunotherapies are changing the treatment of melanoma.
Advertisement
Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, explains how immunotherapies are changing the treatment of melanoma.
Read more about ipilimumab, nivolumab, and other immunotherapies being looked at in melanoma > >
Articles in this issue
almost 12 years ago
The Outlook for CAR-Modified T Cellsalmost 12 years ago
B-Cell Malignancies Faring Well With Immunotherapiesalmost 12 years ago
Update on Immunotherapy and Targeted Combination Therapiesalmost 12 years ago
Progress Made With PD-L1 as Predictive Biomarkeralmost 12 years ago
Oncolytic Viral Therapies About to Spreadalmost 12 years ago
The Future of Immunotherapy Treatments in Lung Canceralmost 12 years ago
Checking in on Checkpoint InhibitorsAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
Building Better ADCs for GI Cancers: Targets, Timing, and Toxicities
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















